PF-07275315 in People with Moderate-to-Very Severe Pulmonary Disease

• Research type

  Research Study

• Full title

  AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

• IRAS ID

  1012475

• Contact name

  Mary-Ellen Boers

• Contact email

  Mary-Ellen.Boers@pfizer.com

• Sponsor organisation

  Pfizer Inc.

• Eudract number

  2024-518587-12

• Clinicaltrials.gov Identifier

  NCT07363694

• Research summary

  An Interventional Phase 2/3, Randomized, Double-Blind, Third Party-Unblinded, Placebo Controlled, Parallel-Group, Study to Investigate Efficacy and Safety of PF-07275315 in Adult Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD).
  Rationale: Study C4531031 is a Phase 2/3 study with the objectives to evaluate the efficacy and safety of PF-07275315 compared to placebo in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD). The study will be conducted in 2 independent stages corresponding to the phase of development: Phase 2 (Stage 1) and Phase 3 (Stage 2). The study will also evaluate the pharmacokinetics (PK), immunogenicity, and biomarkers related to PF-07275315 in both phases.
  The information presented throughout this protocol applies to both Phase 2 and Phase 3 stages of the study, unless otherwise specified.

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  26/SC/0084

• Date of REC Opinion

  11 May 2026

• REC opinion

  Further Information Favourable Opinion